What are the indications, recommended dosing, contraindications, and monitoring requirements for eplerenone?

Eplerenone: Clinical Overview

Indications

Eplerenone is indicated for two primary conditions: heart failure with reduced ejection fraction (HFrEF) post-myocardial infarction and hypertension 1. In HFrEF, it improves survival in stable, symptomatic patients following acute MI. For hypertension, it lowers blood pressure and reduces cardiovascular events, though it may be used alone or combined with other antihypertensives 1.

Heart Failure Context

For patients with primary aldosteronism receiving medical therapy, spironolactone is preferred over eplerenone due to lower cost and wider availability, though all MRAs at equivalent potencies have similar efficacy 2. However, eplerenone's greater mineralocorticoid receptor specificity results in fewer androgen/progesterone-mediated side effects (particularly gynecomastia), making it valuable when spironolactone is not tolerated 3, 4.

In HFrEF with NYHA class II-IV symptoms, MRAs (including eplerenone) are strongly recommended to reduce morbidity and mortality when eGFR >30 mL/min/1.73 m² and potassium <5.0 mEq/L 5.

Dosing Recommendations

Heart Failure Post-MI

• Start: 25 mg once daily
• Target: 50 mg once daily within 4 weeks (as tolerated) 1
• Adjust based on potassium levels per Table 1 in FDA labeling 1

Hypertension

• Start: 50 mg once daily
• Maximum: 50 mg twice daily (100 mg/day total) if inadequate response after 4 weeks 1
• Higher doses provide no additional blood pressure benefit and increase hyperkalemia risk 1

Renal Function Adjustments

For eGFR 31-49 mL/min/1.73 m²: reduce dose by half 5. Evidence from EMPHASIS-HF demonstrates that 25 mg/day in patients with eGFR 30-49 mL/min/1.73 m² is as effective as 50 mg/day in those with eGFR ≥50 mL/min/1.73 m², though adverse events are more common despite lower dosing 6.

Drug Interactions

With moderate CYP3A inhibitors (erythromycin, verapamil, fluconazole, saquinavir):

• Post-MI HFrEF: maximum 25 mg once daily 1
• Hypertension: start 25 mg once daily, maximum 25 mg twice daily 1

Contraindications

Universal Contraindications (All Patients)

• Serum potassium >5.5 mEq/L at initiation 1
• Creatinine clearance ≤30 mL/min 1
• Strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, nelfinavir) 1

Additional Contraindications for Hypertension Only

• Type 2 diabetes with microalbuminuria 1
• Serum creatinine >2.0 mg/dL (males) or >1.8 mg/dL (females) 1
• Creatinine clearance <50 mL/min 1
• Concomitant potassium supplements or potassium-sparing diuretics (amiloride, spironolactone, triamterene) 1

Critical caveat: These contraindications are more restrictive than those for spironolactone, particularly for hypertension, though the evidence basis for some restrictions (e.g., diabetics with microalbuminuria) has been questioned 7.

Monitoring Requirements

Initial Monitoring

Measure serum potassium and creatinine:

• Before initiation 1
• Within first week 1
• At one month after start or dose adjustment 1
• Within 3-7 days of starting ACE inhibitors, ARBs, NSAIDs, or moderate CYP3A inhibitors 1

Ongoing Monitoring

• Periodically thereafter (typically every 6 months if stable) 5
• More frequent monitoring needed in patients with prior severe hypokalemia or renal impairment 2
• For primary aldosteronism: monitor electrolytes, renal function, and renin at 2-3 month intervals during dose titration 2

Potassium Management Algorithm

If potassium 5.5-5.9 mEq/L: reduce dose or temporarily hold 1 If potassium ≥6.0 mEq/L: withhold until <5.5 mEq/L, restart at 25 mg every other day 1 If potassium cannot be maintained <5.5 mEq/L: discontinue to avoid life-threatening hyperkalemia 5

Key Clinical Considerations

Efficacy

Eplerenone reduces systolic BP by 9.21 mmHg and diastolic BP by 4.18 mmHg compared to placebo at doses of 50-200 mg/day 8. Recent meta-analysis suggests eplerenone may have lower all-cause mortality (HR 0.78) and cardiovascular mortality (HR 0.54) compared to spironolactone in HF patients 4, though this requires confirmation in prospective trials.

Tolerability Advantages

Eplerenone has significantly lower rates of:

• Gynecomastia (RR 0.07 vs spironolactone) 4
• Treatment withdrawal (34% vs 53% with spironolactone) 9
• Sexual side effects due to minimal androgen/progesterone receptor affinity 3

Common Pitfalls

1. Hyperkalemia risk is highest with: impaired renal function, diabetes, proteinuria, concomitant ACE/ARB/NSAID use 1
2. Discontinue potassium supplements at days 2-4 of MRA initiation (except severe hypokalemia cases) 2
3. Dietary sodium restriction is critical for optimal MRA response—target <85.5 mmol/day (5 g salt) 2
4. Full therapeutic effect takes 4 weeks for hypertension 1 and up to 3 months for severe primary aldosteronism 2

Special Populations

Pregnancy: Contraindicated in spironolactone labeling; eplerenone has minimal case reports but should be avoided unless no alternatives exist 10. MRAs are contraindicated in primary aldosteronism during pregnancy 2.